From 8930a19ec22ef2905e95c7bbe3b8e11011538391 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 16 Mar 2026 10:41:29 +0000 Subject: [PATCH] extract: 2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes --- ...ney-cardiovascular-and-metabolic-endpoints.md | 6 ++++++ ...-creating-largest-per-patient-cost-savings.md | 6 ++++++ ...ejm-flow-trial-semaglutide-kidney-outcomes.md | 16 +++++++++++++++- 3 files changed, 27 insertions(+), 1 deletion(-) diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index 1222d36b5..155dccbf3 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr - Nature Medicine: additive benefits with SGLT2 inhibitors - First GLP-1 to receive FDA indication for CKD in T2D patients + +### Additional Evidence (confirm) +*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16* + +FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0.56-0.89) and 18% lower risk of major cardiovascular events in a kidney-focused trial, confirming multi-organ protection extends beyond primary endpoints. Separate Nature Medicine analysis showed additive benefits when combined with SGLT2 inhibitors. + --- Relevant Notes: diff --git a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md index 5299ec097..62edf4094 100644 --- a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md +++ b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md @@ -28,6 +28,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, - FDA indication expansion to T2D patients with CKD (2024) - Dialysis cost benchmark: $90K+/year per patient + +### Additional Evidence (confirm) +*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16* + +FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major kidney disease events (HR 0.76, P=0.0003), with annual eGFR slope less steep by 1.16 mL/min/1.73m2 (P<0.001). Trial stopped early for efficacy. FDA subsequently expanded Ozempic indications to include T2D patients with CKD. This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist. + --- Relevant Notes: diff --git a/inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md b/inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md index 4ba699c0a..895788eec 100644 --- a/inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md +++ b/inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md @@ -7,9 +7,13 @@ date: 2024-05-29 domain: health secondary_domains: [] format: paper -status: unprocessed +status: enrichment priority: high tags: [glp-1, semaglutide, CKD, kidney-disease, FLOW-trial, organ-protection] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -38,3 +42,13 @@ Additive benefits when used with SGLT2 inhibitors (separate analysis in Nature M PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: Kidney protection is where GLP-1 downstream savings are largest per-patient — dialysis prevention is the economic mechanism most favorable to the VBC cost-saving thesis EXTRACTION HINT: Focus on the economic implications of slowed kidney decline for capitated payers, not just the clinical endpoint + + +## Key Facts +- FLOW trial enrolled 3,533 patients with type 2 diabetes and chronic kidney disease +- Median follow-up was 3.4 years before early stopping +- Primary endpoint showed HR 0.76 (P=0.0003) for major kidney disease events +- Cardiovascular death reduced by 29% (HR 0.71, 95% CI 0.56-0.89) +- Annual eGFR decline slowed by 1.16 mL/min/1.73m2 with semaglutide +- FDA expanded Ozempic indications to include CKD in T2D patients post-trial +- Dialysis costs approximately $90K+/year per patient in the US